| Serial Number | 86622073 |
| Word Mark | THERADIGM |
| Filing Date | Thursday, May 7, 2015 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, June 24, 2019 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 29, 2016 |
| Goods and Services | Biologics, namely cells and cell lines for scientific and research use in the development, testing and manufacture of therapeutics; Biologics, namely cells and cell lines for scientific and research use in the production of biologic substances, including growth factors and proteins; Biologics, namely cells and cell lines for scientific and research use for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, bone Marrow Stromal Cells (BMSCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, bone Marrow Stromal Cells (BMSCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, bone Marrow Stromal Cells (BMSCs) for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for the testing of chemical substances |
| Goods and Services | Biologics, namely cells and cell lines for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Stem cells and progenitor cells for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Bone Marrow Stromal Cells (BMSCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Adipose tissue stromal cells (ASCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Growth factors for use as medicinal products, namely, cell growth media for growing cells for medical or clinical use; Proteins for use as medicinal products, namely, protein arrays for medical diagnosis purposes; Peptides for use as medicinal products, namely, synthetic peptides for the treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, heart and vasculature disorders, and cancer; Clinical medical reagents, namely, small molecules for use as medicinal products; Clinical medical reagents, namely, telomerase activators (agonists) and inhibitors (antagonists) for use as medicinal products; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of Central Nervous System (CNS) disorders, de-myelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of stroke, spinal cord injury, brain injury, brain tumours, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, peripheral neural disorders, autism, Multiple Sclerosis (MS), and MS-like diseases with the following symptoms: cognitive dysfunction, mobility dysfunction, and neurological disorders; Pharmaceutical preparations for the treatment of the Central Nervous System (CNS), namely stroke, spinal cord injury, brain injury, brain tumours, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, Multiple Sclerosis (MS), and cognitive dysfunction, mobility dysfunction, and neurological disorders, peripheral neural disorders, and autism |
| Goods and Services | Manufacturing of biologics, cells, scaffolds and matrices, and related biological materials |
| Goods and Services | Pharmaceutical research and development services; Biological research and development services; Medical research and development services in the field of regenerative medicine and immunotherapies; Medical and pharmaceutical consultation and research in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical and pharmaceutical consultation in the field of Central Nervous System (CNS) disorders; Medical and pharmaceutical consultation in the field of stroke, spinal cord injury, brain injury, brain tumours, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, de myelinating disorders, auto-immune disorders, peripheral neural disorders, and autism |
| Goods and Services | Medical testing for diagnostic or treatment purposes; Medical treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, and heart and vasculature disorders; Medical treatment of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical treatment of Central Nervous System (CNS) disorders; Medical treatment of stroke, spinal cord injury, brain injury, brain tumours, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical treatment, namely, cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, de myelinating disorders, auto-immune disorders, peripheral neural disorders, and autism |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, February 20, 2016 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, May 15, 2015 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, February 20, 2016 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, May 15, 2015 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, February 20, 2016 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | COGNATE BIOSERVICES, INC. |
| Party Type | 21 - New Owner After Publication |
| Legal Entity Type | 03 - Corporation |
| Address | HANOVER, MD 21076 |
| Party Name | Theradigm, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Bethesda, MD 20814 |
| Party Name | Theradigm, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Bethesda, MD 20814 |
| Event Date | Event Description |
| Monday, June 24, 2019 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, June 24, 2019 | ABANDONMENT - NO USE STATEMENT FILED |
| Tuesday, November 27, 2018 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, November 26, 2018 | EXTENSION 5 GRANTED |
| Thursday, November 15, 2018 | EXTENSION 5 FILED |
| Monday, November 26, 2018 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Thursday, November 15, 2018 | TEAS EXTENSION RECEIVED |
| Friday, May 11, 2018 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, May 9, 2018 | EXTENSION 4 GRANTED |
| Wednesday, May 9, 2018 | EXTENSION 4 FILED |
| Wednesday, May 9, 2018 | TEAS EXTENSION RECEIVED |
| Friday, November 24, 2017 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, November 22, 2017 | EXTENSION 3 GRANTED |
| Wednesday, November 22, 2017 | EXTENSION 3 FILED |
| Wednesday, November 22, 2017 | TEAS EXTENSION RECEIVED |
| Thursday, May 25, 2017 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, May 23, 2017 | EXTENSION 2 GRANTED |
| Tuesday, May 23, 2017 | EXTENSION 2 FILED |
| Tuesday, May 23, 2017 | TEAS EXTENSION RECEIVED |
| Wednesday, November 23, 2016 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, November 21, 2016 | EXTENSION 1 GRANTED |
| Monday, November 21, 2016 | EXTENSION 1 FILED |
| Monday, November 21, 2016 | TEAS EXTENSION RECEIVED |
| Monday, November 21, 2016 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, November 21, 2016 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, May 24, 2016 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, April 20, 2016 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Tuesday, March 29, 2016 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 29, 2016 | PUBLISHED FOR OPPOSITION |
| Wednesday, March 9, 2016 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Saturday, February 20, 2016 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Saturday, February 20, 2016 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, February 19, 2016 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, February 19, 2016 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, August 24, 2015 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, August 24, 2015 | NON-FINAL ACTION E-MAILED |
| Monday, August 24, 2015 | NON-FINAL ACTION WRITTEN |
| Tuesday, August 18, 2015 | ASSIGNED TO EXAMINER |
| Friday, May 15, 2015 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Monday, May 11, 2015 | NEW APPLICATION ENTERED IN TRAM |